Brain Cancer
8 protocols meet the specified criteria.
-
20324
ON-TRK: PrOspective Non-Interventional Study in Patients with Locally Advanced or Metastatic TRK Fusion Cancer Treated with Larotrectinib -
A071601
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas -
A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events -
COG-ACNS1833
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) -
EAY191
Molecular Analysis for Combination Therapy Choice (ComboMATCH) -
F8394-201
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations -
INTRAGO-II
A Multicenter Randomized Phase III Trial on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (INTRAGO II) -
S2013
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study